Ipsen patents expiration
1. Bylvay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7132416 | IPSEN | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(1 year, 8 months ago) | |
| US10975046 | IPSEN | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11732006 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10487111 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10981952 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10093697 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US10011633 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(7 years from now) | |
| US9694018 | IPSEN | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(7 years from now) | |
| US11801226 | IPSEN | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
| US11365182 | IPSEN | Crystal modifications of odevixibat |
Jun, 2039
(15 years from now) | |
| US11802115 | IPSEN | Pharmaceutical formulation of odevixibat |
Jun, 2039
(15 years from now) | |
| US11583539 | IPSEN | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
| New Indication(I-918) | Jun 13, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of reducing serum bile acids in patients 12 months or older suffer...
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
BYLVAY family patents
2. Onivyde patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9724303 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(11 months from now) | |
| US9782349 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(11 months from now) | |
| US8992970 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(11 months from now) | |
| US10722508 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(11 months from now) | |
| US8329213 | IPSEN | Liposomes useful for drug delivery |
Jan, 2027
(2 years from now) | |
| US8147867 | IPSEN | Liposomes useful for drug delivery |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9730891 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(11 months from now) | |
| US8703181 | IPSEN | Liposomes useful for drug delivery |
May, 2025
(11 months from now) | |
| US9492442 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| US9364473 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| US11369597 | IPSEN | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(9 years from now) | |
| US9339497 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| US9452162 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| US9717724 | IPSEN | Methods for treating pancreatic cancer using combination therapies |
Jun, 2033
(9 years from now) | |
| US10980795 | IPSEN | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Jun, 2033
(9 years from now) | |
| US11344552 | IPSEN | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
Aug, 2036
(12 years from now) | |
| US10993914 | IPSEN | Stabilizing camptothecin pharmaceutical compositions |
Oct, 2036
(12 years from now) | |
| US10456360 | IPSEN | Stabilizing camptothecin pharmaceutical compositions |
Oct, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-463) | Feb 13, 2031 |
| New Indication(I-932) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-99) | Oct 22, 2022 |
| Orphan Drug Exclusivity(ODE) | Oct 22, 2022 |
| New Product(NP) | Oct 22, 2018 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer; Treatment of...
Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS
ONIVYDE family patents
3. Sohonos patents
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789074 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(7 years from now) | |
| US9314439 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(7 years from now) | |
| US10292954 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(7 years from now) | |
| US10864194 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(13 years from now) | |
| US11622959 | IPSEN | Methods for treating heterotopic ossification |
Jun, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-439) | Aug 16, 2030 |
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2028 |
Drugs and Companies using PALOVAROTENE ingredient
NCE-1 date: 17 August, 2027
Market Authorisation Date: 16 August, 2023
Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva
Dosage: CAPSULE;ORAL
SOHONOS family patents